Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Common Equity: 2012-2024

Historic Common Equity for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $732.3 million.

  • Amphastar Pharmaceuticals' Common Equity rose 6.74% to $776.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $776.7 million, marking a year-over-year increase of 6.74%. This contributed to the annual value of $732.3 million for FY2024, which is 14.53% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Common Equity of $732.3 million as of FY2024, which was up 14.53% from $639.4 million recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year Common Equity high stood at $732.3 million for FY2024, and its period low was $445.5 million during FY2021.
  • Moreover, its 3-year median value for Common Equity was $639.4 million (2023), whereas its average is $633.5 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Common Equity dropped by 0.71% in 2021, and later increased by 20.95% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Common Equity (Yearly) stood at $448.7 million in 2020, then decreased by 0.71% to $445.5 million in 2021, then increased by 18.66% to $528.7 million in 2022, then grew by 20.95% to $639.4 million in 2023, then rose by 14.53% to $732.3 million in 2024.